Specificity, Inc. SPTY
Set alert
0.21 USD -0.06 -20.89%
As of Nov 3, 12:42 PM ET
0.2136 Day range 0.2336
0.032 52-week range 0.52
- YTD
- +205.14%
- 1 year
- -51.78%
- Open
- 0.2336
- Prev close
- 0.27
- Mkt cap
- 4.01M
- Vol
- 12.00K
- Avg vol
- 51.73K
- EPS
- -0.04
- P/E
- 0.00
More statistics
- Low
- 0.2136
- High
- 0.2336
2Y chart
Signals (100)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Oct 28, 2026 | 6 days ago |
| SMA: Bearish | Oct 27, 2026 | 1 week ago |
| MACD: Sell Signal | Oct 27, 2026 | 1 week ago |
| MACD: Buy Signal | Oct 22, 2026 | 1 week ago |
| MACD: Sell Signal | Oct 12, 2026 | 3 weeks ago |
| SMA: Bearish | Oct 8, 2026 | 3 weeks ago |
| MACD: Buy Signal | Oct 7, 2026 | 3 weeks ago |
| SMA: Bullish | Oct 5, 2026 | 4 weeks ago |
| SMA: Bearish | Sep 29, 2026 | 1 month ago |
| SMA: Bullish | Sep 25, 2026 | 1 month ago |
| SMA: Bearish | Sep 24, 2026 | 1 month ago |
| SMA: Bullish | Sep 23, 2026 | 1 month ago |
| SMA: Bearish | Sep 22, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 9, 2026 | 1 month ago |
| SMA: Bullish | Aug 19, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 10, 2026 | 2 months ago |
| MACD: Sell Signal | Jul 24, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 22, 2026 | 3 months ago |
| SMA: Bearish | Jul 20, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 20, 2026 | 3 months ago |
Newest 20 of 100.
News
- Scribe Therapeutics Reports Preclinical Data at ASGCT 2026 Demonstrating Enhanced Potency and Specificity of Engineered CRISPR Technologies for Epigenetic Silencing and Gene Editing
- Caris Life Sciences Finalizes Achieve 1 Study Results Reinforcing the Superior Sensitivity and Specificity of Caris Detect
- Alamar Biosciences Launches NULISAseq™ Neuro 220 Panel, its largest precision proteomics panel with the sensitivity and specificity to advance neurological disease research
- Alamar Biosciences Launches NULISAseq™ Neuro 220 Panel, its largest precision proteomics panel with the sensitivity and specificity to advance neurological disease research
- Specificity Reports Surge in New Client Partnerships as Strategic Growth Initiatives Begin Delivering Results
- Specificity (OTCID:SPTY) to Present on the Emerging Growth Conference on February 26th, 2026.
- FirstGene Study Demonstrates High Analytical Sensitivity and Specificity for Each Component of the Test
- Specificity (OTCID: SPTY) Launches Strategic Expansion into $600B Home Services Market with Proprietary Human-Only, Intent-Driven Advertising Platform
- Specificity Founder Jason Wood to Host Live X Spaces Discussion on Market Wire News
- Specificity Announces Partnership with A2SPA to Secure Agentic AI Execution in AdTech
Your note
Sign in to keep a note on SPTY — it syncs with the Stock Master app.